

User Manual

PathHunter[®] U2OS TrkA-p75 Bioassay Kit

For Detection of SH2 Recruitment by Ligand-Activated TrkA

For Bioassay Kits

93-0529Y3-00147: 2-Plate Kit

93-0529Y3-00148: 10-Plate Kit

This page is intentionally left blank.

Table of Contents

Important: Please read this entire user manual before proceeding with the assay.

Overview.....	1
Assay Principle.....	1
Materials Provided.....	2
Storage Conditions.....	2
Additional Materials Required	3
Protocol Schematic	4
Detailed Protocol	5
Day 1: Bioassay Cell Preparation	5
Day 3: Sample Preparation	6
Day 3: Ligand-Neutralizing Sample Preparation	7
Day 3: Detection	9
Typical Results	10
Troubleshooting Guide	11
Limited Use License Agreement	12

Table of Figures

Figure 1. Assay Principle.....	1
Figure 2: Agonist serial dilutions	7
Figure 3: Assay Plate Map	8
Figure 5. Typical Results.....	10

For additional information of Technical Support, see contact information at the bottom of this page.

Overview

The PathHunter TrkA-p75 Bioassay kit provides a robust, highly sensitive, and easy-to-use functional cell based assay to study drug potency and neutralizing antibodies. The bioassay kit contains all the materials needed for a complete assay, including cells, detection reagents, cell plating reagent, positive control agonist, and assay plates. The cryopreserved cells have been manufactured to ensure long-term assay reproducibility, and faster implementation from characterization to QC lot release. This bioassay has been optimized for a 96-well format. The protocol can be optimized further for running the assay in a high-throughput 384-well format.

Assay Principle

This bioassay utilizes Enzyme Fragment Complementation (EFC) technology, where the β -galactosidase (β -gal) enzyme is split into two fragments, the ProLink™ (PK), and the Enzyme Acceptor (EA). Independently, these fragments have no β -gal enzymatic activity; however, when forced to complement through protein-protein interactions, they form an active β -gal enzyme.

The PathHunter TrkA-p75 Bioassay monitors Trk-p75 activity by detecting recruitment of the phosphotyrosine-binding SH2 domain of SHC1 as a result of ligand-mediated receptor activation. In this system, TrkA is fused to the small β -gal fragment, PK, and co-expressed in cells stably expressing the untagged co-receptor, p75 (which enhances the specificity of ligand binding, as well as enhances sensitivity of TrkA to low levels of β -NGF). On the other hand, the SH2 domain of SHC1 is fused with the larger enzyme fragment, EA. Activation of TrkA induces receptor dimerization and auto-phosphorylation, leading to SHC1-EA recruitment, and forcing complementation of the two β -galactosidase enzyme fragments. This results in the formation of an active β -gal enzyme, which, upon the addition of the detection reagents, hydrolyzes a substrate to generate a chemiluminescent signal.




Figure 1. Assay Principle: PK-tagged TrkA receptors are activated by the ligand β -NGF, in the presence of the p75 co-receptor (A). Activation of these receptors causes dimerization and autophosphorylation, leading to the recruitment of an EA-tagged SH2 domain-containing protein. This brings the two β -gal fragments in close proximity and forces complementation. The active β -gal enzyme then formed hydrolyzes a substrate to generate a chemiluminescent signal (B).

Materials Provided

List of Components	93-0529Y3-00147	93-0529Y3-00148
PathHunter U2OS TrkA-p75 Bioassay Cells (1.2 x 10 ⁶ cells in 0.1 mL per vial)	2	10
AssayComplete™ Cell Plating 16 Reagent (100 mL per bottle)	1	3
AssayComplete Protein Dilution Buffer (50 mL per bottle)	1	2
Control Agonist: Recombinant Human β-NGF (20 µg per vial)	1	2
PathHunter Detection Kit (mL per bottle)		
Cell Assay Buffer	1 x 11.4	1 x 57
Substrate Reagent 1	1 x 3	1 x 15
Substrate Reagent 2	1 x 0.6	1 x 3
96-Well White, Clear Flat-Bottom, TC-Treated, Sterile Plates with Lid	2	10

Storage Conditions

PathHunter U2OS Trk-p75 Bioassay Cells

Cells are shipped on dry ice and should arrive in a frozen state. To ensure maximum cell viability, store the vials of bioassay cells in the vapor phase of liquid nitrogen as soon as possible upon receipt. Please contact technical support immediately, if the cells received were already thawed.

- Short-term (less than 24 hours): Store vials at -80°C immediately upon arrival. (DO NOT store at -80°C for longer than 24 hours).
- Long-term (longer than 24 hours): Vials should ONLY be stored in the vapor phase of liquid nitrogen.



Safety Warning: A face shield, gloves and lab coat should be worn at all times when handling frozen vials. Use tongs to remove cryovials from liquid nitrogen storage, and place the vials immediately on dry ice in a covered container. Wait at least 1 minute for any liquid nitrogen that may be present inside the vial to evaporate. Do not touch the bottom of the vials at any time to avoid inadvertent thawing of the cells.

AssayComplete Cell Plating 16 Reagent (CP16)

Upon receipt, store at -20°C. Once thawed, the Cell Plating Reagent can be stored at 4°C for up to 4 weeks. For longer storage (up to the expiration date listed in the kit's Certificate of Analysis), the reagent should be aliquoted and stored at -20°C until needed. Avoid multiple freeze-thaw cycles.

To make aliquots suitable for testing one assay plate each, 30 mL of reagent per aliquot can be dispensed and frozen down.

PathHunter® U2OS TrkA-p75 Bioassay Kit User Manual

Control Agonist: Recombinant Human β -NGF

Upon receipt, store at -20°C, until ready to use (up to the date listed in the kit's Certificate of Analysis). Centrifuge the vial before opening to maximize recovery. Once prepared, the excess stock solution can be stored as suitable aliquots (e.g. 30 μ L) at -20°C until needed. Do not freeze/thaw more than twice.

Protein Dilution Buffer

Upon receipt, store at -20°C. Once thawed, the Protein Dilution Buffer can be stored at 4°C for up to 4 weeks. For longer storage (up to the expiration date listed in the kit's Certificate of Analysis), the reagent should be aliquoted and stored at -20°C until needed. Avoid multiple freeze-thaw cycles. To make aliquots suitable for testing one assay plate each, 10 mL of reagent per aliquot should be dispensed and frozen down. This amount may vary depending on the stock sample concentrations, and should be adjusted accordingly.

PathHunter Detection Kit

Upon receipt, store reagents at -20°C. The detection kit is stable until the expiration date listed on the outer label of the kit box. Thaw reagents at room temperature before use. Once thawed, the reagents can be stored for up to 1 month at 2-8°C. For long-term storage (up to the expiration date listed in the kit's Certificate of Analysis), the reagents should be re-frozen in opaque containers at -20°C, until needed.

For the ten-plate kit: If all the plates will not be used at the same time, we recommend making five aliquots for the Cell Assay Buffer and Substrate Reagent 1. Each aliquot will be adequate for two assay plates. Make five aliquots of 11.4 mL each for Cell Assay Buffer, and five aliquots of 3 mL each for Substrate Reagent 1. Sufficient reagent volumes are provided in the kit to make these aliquots. We do not recommend making aliquots of Substrate Reagent 2, as it does not freeze and is often lost while pipetting.

96-Well Tissue Culture-Treated Plates

Store at room temperature.


Additional Materials Required

The following equipment and additional materials are required to perform these assays:

Materials	Ordering Information
96-Well Green, V-Bottom, Untreated, Non-Sterile Dilution Plates	92-0011
Multimode or luminescence plate reader	Refer to Instrument Compatibility Chart at discoverx.com/instrument-compatibility
Sterile disposable reagent reservoir	Thermo Fisher Scientific, Cat. No. 8094 or similar
Humidified tissue culture incubator (37°C and 5% CO ₂)	
Single and multichannel micropipettes and pipette tips (10 μ L-1000 μ L)	
Polypropylene tubes (50 mL and 15 mL)	
Microcentrifuge tubes (1.5 mL)	

Protocol Schematic

Quick-Start Procedure: In a 96-well tissue culture treated plate, perform the following steps:



*Room temperature refers to a range of 23-25°C

Detailed Protocol

This user manual provides a protocol for determining potency in a 96-well format. To run this bioassay in a 384-well format, or to optimize the assay for the detection of neutralizing antibodies, contact Technical Support at DRX_SupportUS@eurofinsUS.com.

Day 1: Bioassay Cell Preparation

The following protocol is for thawing and plating the cryopreserved PathHunter U2OS TrkA-p75 Bioassay Cells from cryovials.

1. Prior to thawing the cells, ensure that all the required materials are set up in the tissue culture hood. These include:
 - a. One sterile 25 mL sterile reagent reservoir
 - b. One sterile 50 mL conical tube
 - c. A micropipette (P1000) set to dispense 1 mL
 - d. A multichannel pipette and tips set to dispense 80 µL
 - e. A bottle of AssayComplete™ Cell Plating 16 Reagent (CP16), pre-warmed in a 37°C water bath for 15 minutes
 - f. A 96-Well White, Clear Flat-Bottom Tissue Culture-Treated Sterile Assay Plate (provided with the kit)
 - g. A 96-Well Green, V-Bottom, Untreated, Non-Sterile Dilution Plate, to be used as the master dilution plate
2. Dispense 19.2 mL of CP16 into the 50 mL conical tube.
3. Remove the cryovial from the liquid nitrogen vapor and immediately place it in dry ice.



DO NOT use a heated water bath to thaw the vial. Hold the cryovials by the cap; **DO NOT** touch the sides or bottom of the vial to avoid thawing of the cell pellet. Wipe down the outside surface of the cryovial quickly with 70% ethanol, and immediately bring it into the tissue culture hood.

4. Add 1 mL of pre-warmed CP16 from the 50 mL conical tube, to the cryovial to thaw the cell pellet. The reagent should be added slowly along the wall of the cryovial tube. Slowly pipet up and down several times to uniformly resuspend the cells.
5. Transfer the cell suspension to the conical tube containing the remaining 18.2 mL of CP16. Remove all the suspension from the cryovial tube to ensure maximum recovery of cells.
6. Replace the cap on the conical tube and mix by gentle inversion several times to ensure that the cells are properly resuspended in the reagent, without creating any froth in the suspension. Pour the suspension immediately into the 25 mL reservoir.
7. Transfer 80 µL of the cell suspension to each well of the 96-well assay plate using a multichannel pipette. Replace the lid and leave the plate at room temperature for 15 minutes to allow the cells to settle uniformly in the well to minimize potential edge effects.
8. Incubate the assay plate at 37°C and 5% CO₂ for 24 hours before proceeding with the assay.

Day 2: Sample Preparation

The following protocol is designed for testing purified biologics. The PathHunter assays can also be run in the presence of high levels of serum or plasma without significantly impacting assay performance. In some assays, standard curves of the control can be prepared in neat serum or plasma, and added directly to cells without further dilution. For best results, the optimized minimum required dilution of crude samples should be determined empirically.

A 1:3 serial dilution for the control agonist, Recombinant Human β -NGF, has been used in this protocol. The volumes listed below are designed for running samples from one dose-response curve in duplicate on the assay plate (Refer to [Figure 3. Representative Assay Plate Map](#)).

1. Add 80 μ L of CP16 to Wells A2 to A12 of the master dilution plate.
2. Prepare the control agonist (β -NGF) dose-response curve:
Recombinant Human β -NGF will serve as a positive control in this assay. The agonist is prepared at 5X the desired final concentration, as it will be diluted 5-fold by adding 20 μ L to 80 μ L of the medium present in the assay plate.
 - 2.1. Add 200 μ L of the supplied Reconstitution Buffer to the vial containing 20 μ g of the lyophilized β -NGF, to make a 100 μ g/mL stock solution. Slowly pipet up and down several times. Make suitable aliquots (e.g. 20 μ L) and store at -20°C until needed.
 - 2.2. In a sterile microcentrifuge tube, prepare a 5X stock of the top dose of β -NGF by adding 7.5 μ L of the 100 μ g/mL stock solution prepared in [Step 2.1](#) into 292.5 μ L of CP16. Mix gently by pipetting up and down several times. This results in a 2.5 μ g/mL solution (5X the final 500 ng/mL highest dose).
 - 2.3. Transfer 160 μ L of the 2.5 μ g/mL solution prepared in [Step 2.2](#) into Well A1 of the master dilution plate.
 - 2.4. Using a clean pipette tip, transfer 40 μ L from Well A1 into Well A2, and mix thoroughly by pipetting up and down several times.
 - 2.5. Replace the pipette tip and transfer 40 μ L from Well A2 to Well A3, and mix well. Repeat this process until Well A11 is reached, resulting in an 11-point, 1:3 dilution series. No sample is transferred to Well A12, as this will serve as a negative control.
3. Prepare any agonist test samples in a similar manner.
4. Remove the assay plate from the incubator and place it in the tissue culture hood.
5. Transfer 20 μ L from each well of the agonist dilution series from the master dilution plate to the appropriate wells of the assay plate, using a multichannel pipette.
6. Incubate the assay plate at room temperature for 3 hours.




Figure 2: Agonist serial dilutions: Make eleven 3-fold serial dilutions of the agonist in a master dilution plate.

7. Prepare the antagonist dilution series. If antagonist samples are not being tested, then skip **Steps 7-12** and proceed to **Day 2: Ligand-Neutralizing Sample Preparation** or **Day 2: Detection**.
 - 7.1. The antagonist is prepared at 10X the desired final concentration, in 11-point dilution series, similar to that described for β -NGF in **Steps 1 and 2**. However, an appropriate top dose and dilution scheme (e.g. a 1:3 dilution scheme) must be determined empirically. No antagonist is added to any wells in Column 12, as these are the negative control wells.
 - 7.2. Remove the assay plate from the incubator and place it in the tissue culture hood.
 - 7.3. Transfer 10 μ L from each well of the antagonist dilution series from the master dilution plate to the appropriate wells of the assay plate using a multichannel pipette.
 - 7.4. Incubate the assay plate at 37°C and 5% CO₂ for 30-60 minutes in a humidified incubator. The optimal incubation time for your antagonist must be determined empirically.
8. Prepare the agonist challenge for the antagonist dilution series: The agonist challenge is prepared at 10X the desired final concentration (e.g. at EC₈₀ of the agonist).
9. Remove the assay plate from the incubator and place it in the tissue culture hood.
10. Transfer the 10X agonist challenge into a reagent reservoir.
11. Transfer 10 μ L of the 10X agonist challenge prepared in **Step 8**, to the appropriate wells (i.e. wells with antagonist dilution series) of the assay plate, using a multichannel pipette.
12. Incubate the assay plate at room temperature for 3 hours.

Day 2: Ligand-Neutralizing Sample Preparation

The following protocol is used for the quantitation of anti-ligand samples (e.g. antibodies or Fc-fusion proteins etc.). The ligand is pre-incubated with the neutralizing sample for 15-30 minutes. However, the optimal incubation time for your sample should be determined empirically, before addition to the assay.

1. Prepare the anti-ligand antibody dilution series at 10X the desired final concentration, in a new row (e.g. row B) of the master dilution plate.
2. Prepare the agonist challenge at 10X the desired final concentration, similar to that described in **Step 8** in **Sample Preparation**.

PathHunter® U2OS TrkA-p75 Bioassay Kit User Manual

- For each dose-response curve, add 45 μ L of the agonist challenge to the appropriate row of a pre-mixing plate (e.g. a V-bottom polypropylene 96-well plate). Transfer 45 μ L of the 10X anti-ligand antibody dilution series to the appropriate row of the pre-mixing plate already containing 45 μ L of the agonist challenge. Mix by slowly pipetting up and down several times.
- Incubate the plate at room temperature for 15-30 minutes. The optimal pre-incubation time for each antibody should be determined empirically.
- Transfer 20 μ L of the 10X anti-ligand antibody and 10X agonist mixture to the appropriate wells of the assay plate.
- Incubate the assay plate at room temperature for 3 hours.




Figure 3: Representative Assay Plate Map: This plate map shows two interdigitated 11-point dose curves, with two replicates per dose point, for two test samples and one reference sample tested using the same dilution scheme.

Day 2: Detection

1. Prepare a working detection solution by mixing the three detection reagent components in a 15 mL conical tube. Refer to the table below for the volume ratio.

Working Detection Solution		
Component	Ratio	Volume per Plate (mL)
Cell Assay Buffer	19	5.7
Substrate Reagent 1	5	1.5
Substrate Reagent 2	1	0.3
Total Volume		7.5

2. Replace the cap of the tube and mix by gentle inversion. Transfer 50 µL (50% of the assay volume) of the working detection solution to the appropriate wells of the assay plate.
3. Incubate the assay plate for 1 hour at room temperature in the dark.



Room temperature refers to a range of 23-25°C.

4. Read samples on a standard luminescence plate reader at 0.1 to 1 second/well for photomultiplier tube readers or 5 to 10 seconds for imager. To determine instrument compatibility, visit discoverx.com/instrument-compatibility.


Data analysis can be performed using any statistical analysis software such as GraphPad Prism, SoftMax Pro, Gen5, or Microsoft Excel etc.

Typical Results

The following graph is an example of a typical dose response curve for the TrkA-p75 Bioassay generated using the protocol outlined in this manual. The data shows potent, dose-dependent SH2 recruitment, when TrkA-p75 is treated with Recombinant Human β -NGF.

The plate was read on the EnVision® Multimode Plate Reader and data analysis was conducted using GraphPad Prism.

A.



B.

EC ₅₀ (ng/mL)	1.57
S/B	8.1

Figure 5. Typical Results: Representative **A**, dose-response curve and **B**, EC₅₀ and assay window for Recombinant Human β -NGF-mediated activation of TrkA-p75.

Troubleshooting Guide

Problem	Potential Cause	Proposed Solution
No response	Incorrect thawing procedure	Refer to the thawing instructions in the Bioassay Cell Preparation section of this user manual.
	Incorrect ligand used or improper ligand incubation time	Refer to the datasheet for recommended ligand and assay conditions.
	Incorrect preparation of the ligand (agonist or antagonist)	Refer to the vendor-specific datasheet to ensure proper handling, dilution, and storage of the ligand.
	Sub-optimal time course for induction	Optimize time course of induction with agonist and antagonist.
Low or no signal	Incorrect preparation of detection reagents	Detection reagents are sensitive to light and should ideally be prepared just prior to use.
	Problem with microplate reader	The microplate reader should be in luminescence mode. Read at 0.1-1 second/well.
Experimental S/B does not match the value noted in the Certificate of Analysis	Incorrect incubation temperature	Confirm assay conditions. Check and repeat the assay at the correct incubation temperature as indicated on the assay datasheet.
	Incorrect preparation of ligand (agonist or antagonist)	Some ligands are difficult to handle. Confirm the final concentration of ligands.
	Sub-optimal agonist challenge concentration	Perform agonist curve to reassess EC ₈₀ with the ligand provided in the kit. Perform antibody titrations with EC ₈₀ and EC ₉₀ agonist challenge concentrations to re-optimize the assay window.
EC ₅₀ is right-shifted	Improper ligand handling or storage	Check ligand handling requirements
	Difference in agonist binding affinity	Refer to the Certificate of Analysis for the ligand provided in the kit to confirm that the ligand used is comparable.
	Problems with plate type and compound stability	Hydrophobic compounds should be tested for solubility and may require evaluation in different dilution buffers. Non-binding surface plates may be necessary for hydrophobic compounds.

For questions on using this product, please contact Technical Support at [1.866.448.4864](tel:1.866.448.4864) or DRX_Support@eurofinsUS.com

Limited Use License Agreement

These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License.

Please visit discoverx.com/license for limited use label license and trademark information for this product.

Contact Information

Eurofins DiscoverX

42501 Albrae Street, Fremont, CA 94538

Web: discoverx.com/bioassays

Phone: 1.866.448.4864

Technical Support: DRX_SupportUS@eurofinsUS.com